Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABS) Non-cash Items (2021 - 2025)

SAB Biotherapeutics (SABS) has disclosed Non-cash Items for 5 consecutive years, with $38.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Non-cash Items rose 3103.91% year-over-year to $38.0 million, compared with a TTM value of $38.0 million through Dec 2025, up 3103.91%, and an annual FY2025 reading of $38.0 million, up 3103.91% over the prior year.
  • Non-cash Items was $38.0 million for Q4 2025 at SAB Biotherapeutics, up from $8500.0 in the prior quarter.
  • Across five years, Non-cash Items topped out at $38.0 million in Q4 2025 and bottomed at $8500.0 in Q3 2025.
  • Average Non-cash Items over 5 years is $7.1 million, with a median of $3.6 million recorded in 2023.
  • The sharpest move saw Non-cash Items crashed 99.62% in 2022, then soared 3103.91% in 2025.
  • Year by year, Non-cash Items stood at $28.9 million in 2021, then plummeted by 99.62% to $109891.0 in 2022, then skyrocketed by 505.12% to $664967.0 in 2023, then surged by 78.36% to $1.2 million in 2024, then skyrocketed by 3103.91% to $38.0 million in 2025.
  • Business Quant data shows Non-cash Items for SABS at $38.0 million in Q4 2025, $8500.0 in Q3 2025, and $5.2 million in Q2 2025.